NEW YORK (GenomeWeb) – Roche will collaborate with the Garvan Institute of Medical Research in Sydney to develop technology for targeted next-gen sequencing-based epigenomic analysis, the company said today.

Under the terms of the two-year discovery agreement, researchers at the Garvan Institute will use Roche NimbleGen's SeqCap Target Enrichment System to develop new methods for accurately analyzing regions of the epigenome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.